• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.

作者信息

Bolis G, D'Incalci M, Belloni C, Mangioni C

出版信息

Cancer Treat Rep. 1979 Aug;63(8):1375-7.

PMID:113096
Abstract

Thirty-four patients resistant to cyclophosphamide and Adriamycin received hexamethylmelamine at one of two dose regimens: 6 mg/kg/day orally for 21 days every 4 weeks or 8 mg/kg/day orally for 21 days every 6 weeks. Only five patients responded. Tolerance to the drug was, however, satisfactory; nausea, pyrosis, and vomiting were the only frequent side effects. Myelosuppression occurred in only one case.

摘要

相似文献

1
Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Cancer Treat Rep. 1979 Aug;63(8):1375-7.
2
Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):172-3.
3
Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):137-41.
4
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Cancer Treat Rep. 1982 May;66(5):1233-4.
5
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.用于卵巢癌的六药联合化疗(六甲蜜胺、阿霉素、顺铂、环磷酰胺、甲氨蝶呤和5-氟尿嘧啶;CHAMP-5):联合方案的交替序列
Cancer Treat Rep. 1985 Jun;69(6):689-93.
6
Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.单药阿霉素治疗后联合六甲蜜胺-环磷酰胺治疗晚期卵巢癌。
Gynecol Oncol. 1982 Oct;14(2):262-70. doi: 10.1016/0090-8258(82)90098-1.
7
cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.顺铂、阿霉素和六甲蜜胺与环磷酰胺治疗晚期卵巢癌的对比研究
Cancer Chemother Pharmacol. 1983;10(2):100-3. doi: 10.1007/BF00446218.
8
Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):149-51.
9
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.六甲蜜胺用于铂耐药和铂难治性卵巢癌:妇科肿瘤学组II期试验
Gynecol Oncol. 1998 Jun;69(3):226-9. doi: 10.1006/gyno.1998.5016.
10
Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
Cancer Treat Rep. 1985 Nov;69(11):1243-8.

引用本文的文献

1
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.六甲蜜胺。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007.
2
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.六甲蜜胺及其代谢产物体外细胞毒性的时间依赖性。
Br J Cancer. 1980 Apr;41(4):630-5. doi: 10.1038/bjc.1980.106.
3
Developing new drugs for ovarian cancer: a challenging task in a changing reality.
开发卵巢癌新药:在不断变化的现实中的一项具有挑战性的任务。
J Cancer Res Clin Oncol. 1984;107(2):111-24. doi: 10.1007/BF00399382.
4
N-methyl antitumour agents. A distinct class of anticancer drugs?N-甲基抗肿瘤药物。一类独特的抗癌药物?
Cancer Chemother Pharmacol. 1987;19(2):91-102. doi: 10.1007/BF00254559.